AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per ...

CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said ...

AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...

CEO Soriot said Europe must boost investment in pharma innovation or risk falling further behind the US in drug development.

LONDON (Reuters) -AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

CEO Albert Bourla is waiting for the US government to decide whether to place a 25% tariff on pharmaceutical imports.

CEO Pascal Soriot said Europe was "falling behind" in attracting investment and needed to "invest more in what really matters ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...